Loading...
•
Jun 30, 2022
Reneo Pharmaceuticals Q2 2022 Earnings Report
Reported financial results for the second quarter of 2022.
Key Takeaways
Reneo Pharmaceuticals reported a net loss of $12.3 million, or $0.50 per share, for the three months ended June 30, 2022. The company had approximately $127 million in cash, cash equivalents and short-term investments as of June 30, 2022.
Reported positive results from REN001 Phase 1b long-chain fatty acid oxidation disorders (LC-FAOD) study
Announced plans to initiate a third REN001 program in primary mitochondrial myopathies (PMM) patients with nuclear DNA (nDNA) defects
Roshawn Blunt was appointed to the Board of Directors
Two-thirds enrollment in the pivotal STRIDE study was achieved, gaining alignment on the planned registration plan in Europe
Forward Guidance
The company anticipates completion of enrollment in the pivotal STRIDE study by year-end 2022 and meetings with regulatory agencies to discuss LC-FAOD and nDNA PMM programs in 4Q22/1Q23.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...